[go: up one dir, main page]

ZA200703716B - Improved dosing regimen of temozolomide for treating cancer based on the patient's MGMT level - Google Patents

Improved dosing regimen of temozolomide for treating cancer based on the patient's MGMT level

Info

Publication number
ZA200703716B
ZA200703716B ZA200703716A ZA200703716A ZA200703716B ZA 200703716 B ZA200703716 B ZA 200703716B ZA 200703716 A ZA200703716 A ZA 200703716A ZA 200703716 A ZA200703716 A ZA 200703716A ZA 200703716 B ZA200703716 B ZA 200703716B
Authority
ZA
South Africa
Prior art keywords
temozolomide
patient
treating cancer
dosing regimen
cancer based
Prior art date
Application number
ZA200703716A
Other languages
English (en)
Inventor
Zong Chen
Winograd Benjamin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36168622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200703716(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200703716B publication Critical patent/ZA200703716B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G01N2333/91017—Methyltransferases (general) (2.1.1.) with definite EC number (2.1.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200703716A 2004-11-09 2007-05-08 Improved dosing regimen of temozolomide for treating cancer based on the patient's MGMT level ZA200703716B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62625804P 2004-11-09 2004-11-09

Publications (1)

Publication Number Publication Date
ZA200703716B true ZA200703716B (en) 2008-09-25

Family

ID=36168622

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703716A ZA200703716B (en) 2004-11-09 2007-05-08 Improved dosing regimen of temozolomide for treating cancer based on the patient's MGMT level

Country Status (13)

Country Link
US (2) US20060100188A1 (xx)
EP (1) EP1830845A2 (xx)
JP (2) JP2008519584A (xx)
CN (1) CN101098696A (xx)
AU (1) AU2005304672B2 (xx)
BR (1) BRPI0517976A (xx)
CA (1) CA2585446A1 (xx)
MX (1) MX2007005581A (xx)
NO (1) NO20072931L (xx)
NZ (1) NZ554831A (xx)
TW (1) TW200630089A (xx)
WO (1) WO2006052976A2 (xx)
ZA (1) ZA200703716B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0307802B8 (pt) * 2002-02-22 2021-05-25 Merck Sharp & Dohme formulação farmacêutica compreendendo temozolomida, processo para a produção da mesma, bem como artigo fabricado contendo pó liofilizado compreendendo temozolomida
CA2585446A1 (en) * 2004-11-09 2006-05-18 Schering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level
US20070111979A1 (en) * 2005-11-07 2007-05-17 Walter Robert Bishop Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule
RS53082B (sr) * 2006-01-17 2014-06-30 Abbvie Bahamas Ltd. Kombinovana terapija sa parp inhibitorima
NZ571693A (en) 2006-04-05 2011-12-22 Opko Health Inc Pharmaceutical formulations: salts of 8-[{ 1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy} -methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
AR060353A1 (es) 2006-04-05 2008-06-11 Schering Corp Sales de hidrocloruro de 8 - [( 1- (3,5 -bis- (trifluorometil) fenil) -etoxi) -metil] -8-fenil-1,7 -diaza- spiro [4.5] decan -2-ona. composiciones farmaceuticas
WO2007133496A2 (en) * 2006-05-09 2007-11-22 Schering Corporation Development of a novel assay for mgmt (methyl guanine transferase)
AR061618A1 (es) * 2006-06-26 2008-09-10 Schering Corp Formas de dosificacion unitaria de temozolomida
CN101678002A (zh) * 2007-05-08 2010-03-24 先灵公司 使用含有替莫唑胺的静脉注射用配制剂的治疗方法
US20080319039A1 (en) * 2007-06-25 2008-12-25 Jacqueline Rose Bersch Unit dosage forms of temozolomide
US8435972B2 (en) * 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
CN113730412A (zh) * 2013-04-17 2021-12-03 西格诺药品有限公司 用二氢吡嗪并-吡嗪治疗癌症
US10206942B2 (en) 2015-04-10 2019-02-19 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
CN110408694A (zh) * 2018-04-26 2019-11-05 胤安国际（辽宁）基因科技股份有限公司 评估替莫唑胺在治疗脑胶质瘤患者的敏感性的新方法
US20220195440A1 (en) * 2019-03-28 2022-06-23 Thomas Jefferson University Methods for treating cancers using antisense
WO2023113538A1 (ko) * 2021-12-17 2023-06-22 숙명여자대학교산학협력단 뇌종양 치료를 위한 글리세오플빈 병용요법
CN119318654A (zh) * 2024-12-16 2025-01-17 中国医学科学院基础医学研究所 氟达拉滨和替莫唑胺联用在治疗脑胶质瘤中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260291A (en) * 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5876146A (en) * 1995-10-27 1999-03-02 General Electric Company Apparatus and methods for repairing jet pump diffusers in a nuclear reactor
US5786146A (en) * 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) * 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US6346524B1 (en) * 1999-03-30 2002-02-12 Schering Corporation Cancer treatment with temozolomide
HK1044111B (en) * 1999-03-30 2006-02-24 Merck Sharp & Dohme Corp. Improved cancer treatment with temozolomide
AU2001272909A1 (en) * 2000-05-12 2001-11-20 Duke University Assessing levels of o6-alkylguanine-dna alkyltransferase in vivo
EP1328656A4 (en) * 2000-09-29 2005-09-14 Univ Johns Hopkins Med METHOD OF PREDICTING CLINICAL REACTION TO CHEMOTHERAPEUTIC TREATMENT WITH ALKYLATING AGENTS
CA2427319A1 (en) * 2000-10-30 2002-12-27 Gene Logic, Inc. Partially double-stranded nucleic acids, methods of making, and use thereof
WO2002040470A1 (en) * 2000-11-20 2002-05-23 Takeda Chemical Industries, Ltd. Imidazole derivatives, process for their preparation and their use
US20060183168A1 (en) * 2002-10-28 2006-08-17 Geroni Maria C Method for optimizing therapeutic efficacy of nemorubicin
US7718364B2 (en) * 2003-03-25 2010-05-18 John Wayne Cancer Institute DNA markers for management of cancer
CA2585446A1 (en) * 2004-11-09 2006-05-18 Schering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level
US20070111979A1 (en) * 2005-11-07 2007-05-17 Walter Robert Bishop Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule

Also Published As

Publication number Publication date
WO2006052976A2 (en) 2006-05-18
CA2585446A1 (en) 2006-05-18
NO20072931L (no) 2007-08-03
NZ554831A (en) 2009-10-30
US20060100188A1 (en) 2006-05-11
AU2005304672A1 (en) 2006-05-18
EP1830845A2 (en) 2007-09-12
WO2006052976A3 (en) 2006-08-17
BRPI0517976A (pt) 2008-10-21
CN101098696A (zh) 2008-01-02
MX2007005581A (es) 2007-05-23
AU2005304672B2 (en) 2010-03-11
US20090247598A1 (en) 2009-10-01
JP2011121960A (ja) 2011-06-23
JP2008519584A (ja) 2008-06-12
TW200630089A (en) 2006-09-01

Similar Documents

Publication Publication Date Title
ZA200703716B (en) Improved dosing regimen of temozolomide for treating cancer based on the patient's MGMT level
IL206984A0 (en) Analoges of benzoquinone-containing ansamycins for the treatment of cancer
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
IL210401A0 (en) Combination treatment for non - hematologic malignancies using an anti-ogf-1r antibody
IL164599A0 (en) Combination therapy for the treatment of cancer
AU2003234634A8 (en) Drug therapy for celiac sprue
IL164896A0 (en) Immunoconjugates for the treatment of tumours
IL180929A0 (en) The use of n-aryl diazaspiracyclic compounds in the treatment of addiction
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
EP1651211A4 (en) COMBINATION OF MEDICAMENTS FOR THE TREATMENT OF NEOPLASMS
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1757282A4 (en) USE OF KAURANE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS
IL178827A0 (en) Use of reboxetine for the treatment of pain
GB0515261D0 (en) Handheld medical reference application with integrated dosage calculator
MXPA03006412A (es) Metodos para administrar analogos de epotilona para tratamiento de cancer.
AU2003296545A8 (en) Use of a trpm8-activating substance for the treatment of tumours
HK1108382A (en) Improved dosing regimen of temozolomide for treating cancer based on the patient's mgmt level
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
ZA200604365B (en) Compositions and methods for the diagnosis and treatment of tumor
EP1765990A4 (en) THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC AGENTS AGAINST HEPATITIS B